Membrane lipid therapy: Modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment

Pablo V. Escribá a, Xavier Busquets a, Jin-ichi Inokuchi b, Gábor Balogh c, Zsolt Török c, Ibolya Horváth c, John L. Harwood d,*, László Vígh c,*

a Department of Biology, University of the Balearic Islands, E-07122 Palma de Mallorca, Spain
b Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University, Sendai, Japan
c Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary
d School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK

Article info
Article history:
Received 28 January 2015
Received in revised form 10 April 2015
Accepted 29 April 2015
Available online 9 May 2015

Keywords:
Membrane lipid structure
Membrane–protein interactions
Membrane cell signaling
G protein–membrane interactions
Membrane-lipid therapy drugs

Abstract

Nowadays we understand cell membranes not as a simple double lipid layer but as a collection of complex and dynamic protein–lipid structures and microdomains that serve as functional platforms for interacting signaling lipids and proteins. Membrane lipids and lipid structures participate directly as messengers or regulators of signal transduction. In addition, protein–lipid interactions participate in the localization of signaling protein partners to specific membrane microdomains. Thus, lipid alterations change cell signaling that are associated with a variety of diseases including cancer, obesity, neurodegenerative disorders, cardiovascular pathologies, etc. This article reviews the newly emerging field of membrane lipid therapy which involves the pharmacological regulation of membrane lipid composition and structure for the treatment of diseases. Membrane lipid therapy proposes the use of new molecules specifically designed to modify membrane lipid structures and microdomains as pharmaceutical disease-modifying agents by reversing the malfunction or altering the expression of disease-specific protein or lipid signal cascades. Here, we provide an in-depth analysis of this emerging field, especially its molecular bases and its relevance to the development of innovative therapeutic approaches.

© 2015 Elsevier Ltd. All rights reserved.
1. Introduction

Since the first general structure of cellular membranes was published in the 1970s by Singer and Nicolson [1] numerous studies have expanded upon this to further define its complex structure. In a cell membrane bilayer, hundreds to thousands of different lipid species form a heterogeneous cell boundary with multiple structural and functional properties [2]. The same membrane sequestration strategy that separates the interior of cells from the rest of the world is also used for separating the cellular interior into a collection of membrane-bound organelles. The lipid classes that form the different types of cell membranes (Fig. 1) are usually not homogeneously distributed but can form microdomains that act as complex signaling platforms (together with proteins) due to their membrane lipid (structure) preferences. For example, interaction of receptor tyrosine kinases (e.g., EGFR) with Ras, and of Ras with Raf, to propagate proliferation signals into the cell benefits from their common preference for certain membrane microdomains to establish physical productive interactions [3]. Similarly, G protein-coupled receptors (GPCRs) and G proteins exhibit similar membrane lipid environment preferences [2,4,5].

Membrane functions are altered in a wide range of human diseases and this has led to the concept that components of the plasma membrane, for example, specific lipids, enzymes or transcription factors can be targeted to alter its composition and structure [6–8]. This, in turn, would affect the localization and activity of key proteins, or key protein–protein interactions in specific membrane microdomains, and thereby affect signaling cascades. This approach is termed membrane lipid therapy (MLT). Indeed, several studies have now demonstrated the potential of MLT and, although the first clinical trials of rationally designed lipids to regulate the membrane composition and structure to treat cancer and diabetes only began recently (e.g., ClinicalTrials.gov Identifier NCT01792310), other trials using natural lipids were already ongoing (e.g., docosahexaenoic acid (DHA) for Alzheimer’s disease: ClinicalTrials.gov Identifier NCT00440050). In this article, the rationale behind targeting the plasma membrane and the different approaches that can be used to modulate its lipid composition, structure and function is provided. Later, we discuss the current state of the art in various therapeutic indications.

2. Molecular bases underlying MLT

A great many cellular functions occur in or around membranes [2], which suggests that changes in the membrane composition and structure could be relevant to the proper functioning of the cells. In the plasma membrane, hundreds of different lipid species can be found. Some of them have a negative charge, which can promote interactions with positively charged amino acids in proteins [4,7]. Other lipids have a small polar head (e.g., phosphatidylethanolamine), allowing docking of bulky protein lipid anchors (e.g., isoprenyl moieties present in Ras: [9]). Other membrane lipids have a bigger polar head and form tightly packed areas where only certain fatty acids (e.g., myristic or palmitic acid) can intercalate to aid proteins (e.g., Gx protein) to bind to membrane regions where these lipids are abundant. Therefore, the membrane lipid composition can have a profound role in cell signaling. Changes in the type and abundance of lipids in membranes induce alterations in the propagation of cell messages that can be associated with pathological states or with its therapy. In the following paragraphs we will describe important structural features of membranes and proteins that participate in protein–lipid interactions and can be regulated by MLT drugs.

Thus, it has been seen that a high consumption of saturated or trans-unsaturated fatty acids induce increases in the proportion of...
saturated and decrease of unsaturated fatty acids in cell membranes [10]. Membrane fatty acid composition changes may, in turn, alter receptor-mediated cell signaling (e.g., [11]) and cause, among other health problems, cardiovascular diseases [12]. Different fatty acids can have specific effects on the membrane lipid structure and the formation of membrane microdomains [13,14]. Their influence on the membrane lipid structure can then alter the propagation of signals from G protein-coupled receptors to G proteins, exerting an even greater control on cell signals than receptor agonists and antagonists [8]. Therefore, it is feasible to design therapeutic interventions targeting the membrane lipid composition and structure [5].

2.1. Membrane microdomains: signaling platforms

Lipids are not usually homogeneously distributed in the membrane. They form microdomains that confer specific physico-chemical properties to discrete regions of the bilayer. A variety of raft microdomains with different compositions and biochemical properties have been reported [15]. Sphingomyelin (SM), glycosphingolipids (GSLs) and cholesterol (Chol) are abundant in lipid rafts, and form rigid and liquid ordered (Lo) microdomains. Regions with higher phosphatidylethanolamine (PE) content are more fluid and have a weaker surface pressure because the small polar heads of these lipids produce a lower surface packing density and greater lipid disorder (liquid disordered microdomains, Ld) [16]. The heterogeneous distribution of lipids gives rise to both transient (e.g., lipid rafts, caveolae, coated pits, etc.) or stable (e.g., synaptosomes, tight junctions, brush border, etc.) membrane microdomains, a segregation that is favoured by lipids such as Chol [17,18] and specific proteins [15,17].

Proteins involved in signal transduction interact with distinct membrane microdomains, and the association converts these structures into signaling platforms (termed signalosomes) essential for the cell’s physiology. Moreover, they may contain incomplete signaling cascades that can be activated when one further signaling entity (e.g., the receptor) is recruited to the lipid raft [19]. Both physiological and pathological situations can change the cell membrane lipid composition, the biophysical properties of microdomains and, consequently, the proteins they contain and the signals they propagate. In fact, alterations in lipid raft composition and structure have been associated with different pathologies [20,21] and therefore, drug-induced regulation of membrane lipid composition and structure (MLT) can modulate cell signaling, offering potentially effective treatments for a variety of conditions [5,22–24].

2.2. G proteins

G proteins constitute an example of extrinsic membrane proteins whose localization to membrane microdomains and activation is regulated by their interaction with membrane lipids. In the vicinity of GPCRs, there is generally a molar excess of the heterotrimeric (pre-active protein made up of one alpha, beta and gamma subunit, Gαβγ) G proteins to ensure signal amplification. The Gαβγ binding to the Ld regions of the membrane is promoted by (i), the bulky isoprenyl moiety of the Gγ subunit, and (ii) the combined action of PE and the membrane spanning helices of GPCRs to induce a non-lamellar phase propensity [4,9,25]. Upon ligand binding, GPCR-mediated activation of the G protein causes the exchange of GDP for GTP in the Gα subunit, which dissociates from the Gβγ dimer and translocates to lipid rafts due to its greater preference for Lo microdomains [4]. In Lo microdomains, the Gα subunit may activate effector proteins, like adenylyl cyclase, phospholipase C or ion channels among many. By contrast, the Gβγ dimer remains in the Ld microdomains, due to the isoprenyl...
moiety and a polybasic amino acid domain at the C-terminal region of G談, and it either recruits G protein-coupled receptor kinase (GRK) to phosphorylate and inactivate the GPCR, or it activates other effectors [26,27]. Phosphorylated GPCR molecules can be bound by β-arrestin and translocated from the LD microdomains to clathrin microdomains (coated pits), where the receptor will be internalised by endocytosis. Subsequently, its activity can be restored by phosphatases and its recycling to the plasma membrane [26]. In this context, controlling membrane composition and structure can be used to treat pathologies where GPCRs and/or G proteins are altered.

2.3. Protein kinase C

Upon activation, protein kinase C (PKC) isozymes are translocated to the plasma membrane, where they become activated and phosphorylate a wide variety of protein targets. Recruitment of PKC to LD membrane microdomains is favoured by: (i) its specific interactions with the H二-prone lipid DAG, and the negatively charged lipids phosphatidylserine (PS) and phosphatidylinositol (PI); and/or (ii), its preference for microdomains with high non-lamellar phase propensity (rich in PE, DAG, etc.) [28].

Moreover, reducing the non-lamellar (H二) phase propensity by the anticancer drug daunorubicin induces PKCa translocation to the cytoplasm, whereas an increase in the non-lamellar phase propensity (produced by adding PE) provokes the recovery of PKCa at the membrane [29].

PKC binding to membranes is not only regulated by lipid structures but also by specific membrane lipids, both factors that define its sub-localization to specific membrane microdomains [28]. Thus, the C1 domain in the N-terminal region of conventional and novel PKC isozymes can bind to the H二-prone lipids, DAG and phospholipid esters, and it possibly recognizes non-lamellar phases [30]. By contrast, the C1 domain of atypical PKC isozymes recognizes ceramide (Cer) [30]. The C1 domain of PKCa and β contains a Cys and His rich motif that tightly binds two zinc ions and one DAG or phorbol ester molecule. In addition, Asp residues in the C2 domain (which lies near the C1 domain in the regulatory region of the enzyme) of conventional and novel PKC isozymes participate in the binding of Ca^{2+} ions, which is necessary for the further binding of PS and its cytosol-to-membrane translocation [31,32]. Moreover, basic amino acid residues (e.g., Asn and Arg) participate in the binding of additional acidic phospholipid molecules. The presence (conventional and novel) or absence (atypical) of C2 domains, or the molecular differences found in this motif, explain the different protein–lipid interactions among PKC isozymes and the fine-tuning that underlies their differential membrane localization [33]. For example, a Lys rich cluster in the C2 domain also binds the membrane phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), inducing PKCa activation in a manner distinct from that of other membrane lipids [34]. Some studies indicate that the presence of PIP2 determines the localization of the enzyme to the plasma membrane but not to other internal membranes [35]. Therefore, interactions of PKC isozymes with defined lipids or lipid structures in part determine the type of targets that the enzyme will phosphorylate in a given microdomain of the cell's membranes [30].

The C2 domain that is present in PKC and other proteins is not the only lipid-interacting domain that recognizes phosphoinositides. Diverse protein motifs (e.g., pleckstrin homology [PH] domains, FYVE zinc finger domains, PX domains, epsin N-terminal homology [ENTH] domains, clathrin assembly lymphoid myeloid [CALM] domains, PSD95-Dlg1-zo-1 [PDZ] domains, phosphotyrosine-binding [PTB] domains, 4.1 protein-ezrin-radixin-moesin [FERM] domains, etc.) can bind different inositol lipids that localize to different cell membranes [36]. The presence of phosphoinositides in specific membrane microdomains facilitates protein docking to these membrane regions and, moreover, some of these protein domains themselves are also directly involved in protein–protein interactions (e.g., PH and PTB domains) [37]. In some cases, these protein domains mediate the binding to various phosphoinositides. Thus, differences in the PH domain sequence produce variations in protein affinity and in the specificity for the various forms of membrane phosphoinositides (such as PIP2, PIP3, etc.) [38]. In other cases, the PI recognition domain has a more defined preference in different proteins, such as the FYVE domain that appears in proteins that regulate vesicular sorting through specific interactions with PIP3 [39].

In summary, defined membrane lipid classes, such as acidic phospholipids (e.g., PS or PI), PE or DAG, and membrane lipid structures, such as H二-prone or lamellar-prone (Lo or Ld) bilayers, influence the localization of proteins to membrane microdomains via protein–lipid interactions, facilitating specific protein–protein interactions and their resulting signals [28,29,31,32,34]. Therefore, regulating the membrane lipid composition through pharmaceutical or nutraceutical interventions can serve to normalize signals that have been altered under different (pathological) conditions.

2.4. Sphingomyelin synthase and cell proliferation

Membrane lipid composition can be altered by food intake but is mainly controlled by regulation of the activity of a number of enzymes. While many enzymes are important in the cell's physiology, the relevant role of sphingomyelin synthase (SGMS) has been highlighted recently. This enzyme catalyzes the reversible conversion of PC and Cer into SM and DAG. Recent studies showed that tumor cells, with uncontrolled proliferation have lower levels of SM and higher of PE than non-tumor cells [40]. The ca. 10-fold difference in the PE:SM ratio between proliferating cancer cells and normal cells has been suggested to constitute a switch that would enable certain type of proliferation signaling proteins to bind to the membrane and propagate cell growth messages when the cell has a high PE:SM ratio [41].

2.5. The stress response

Cells and their membranes respond rapidly to various environmental perturbations. It has been demonstrated that subtle membrane alterations are critically involved in the conversion of signals from the environment into the transcriptional activation of stress genes (e.g. heat shock protein (Hsp) genes) [42]. Moreover, the specificity of the stress gene expression can be regulated by the particular occurrence and distribution of membrane microdomains (rafts, caveolae, lipid shells, etc.) that precisely sense biological and physical changes [43,44].

Furthermore, it has also been shown that interactions between specific domains of membranes and certain Hsps remodel the pre-existing architecture and physical order of membranes [45]. This feed-back loop allows interactions which antagonize the heat-induced membrane lipid disorganization and can preserve, at least temporarily, membrane structure and functions during stress. Since highly specific Hsp–lipid interactions are known, these provide a means of targeting Hsps to distinct compartments in the membrane such as lipid rafts which are known to be central to many signaling pathways [6].

Linking membrane microdomain structure and physical states with the regulation of heat shock gene expression, together with the feedback effect of certain Hsps in restoring membrane structure/function, may represent a ‘unifying theory’ in which membrane microdomains are key players in a new modality of gene expression [42]. This implies a new way of controlling membrane signaling cascades through physical state which consequently
has widespread implications for health and disease (see Section 3.1).

2.6. Heterogeneity of membrane composition

The lipid and protein composition of plasma membranes from different cell types is very different. Therefore, the presence or absence of given lipids will differentially affect the biophysical properties of the lipid bilayer and protein activities. Moreover, the individual membrane microdomains in the same cell membrane will be differentially affected by the presence or absence of a given molecule (see below the effect of Cer on Chol-rich lipid rafts). Thus, monounsaturated fatty acid treatments can change the order of Lo and Ld microdomains [40,46]. In addition, the cell is full of organelles and membranous structures with specific lipid and protein compositions. In this scenario, all players can be modulated by MLT approaches. Thus, the overall membrane lipid composition, the composition of membrane microdomains or the composition of internal organelles can be targeted by natural or modified lipids or drugs [47–49]. In this context, fatty acids regulate the biophysical properties of membranes according to their structure. Thus, the cis-monounsaturated fatty acid, oleic acid, induces the formation of nonlamellar phases in model membranes, whereas its saturated (stearic) and trans-monounsaturated (elaidic acid) analogs do not [13]. The type and abundance of different lipid classes and their fatty acid composition define the types of membrane microdomains that form platforms where signaling partners have productive interactions. This has been used to design synthetic fatty acids that regulate the membrane microdomain organization in a similar fashion to that of natural lipids [14]. This approach has been used to regulate protein–protein interactions in lipid rafts and other membrane microdomains [41,50]. Thus, MLT appears to be an elegant approach to make protein–protein interactions susceptible to drug therapy where they are frequently considered to be a difficult target [51].

In general, membranes are formed by hundreds of different lipid molecular species and they participate in different functions either as single molecules or as structures formed by several molecules. The multiple functions of membranes depend on these lipids, which confer relevant functions to cells. For example, it has been recently reported that the membrane lipid composition constitutes a proliferation switch in tumor cells [47].

3. Molecular bases of targeting the plasma membrane

We describe five different types of regulatory effects in which the plasma membrane is involved (Fig. 2) and can be exploited for therapeutic purposes. These classifications are based on the way the membrane lipid composition is regulated or protein-membrane interactions are controlled.

3.1. Type 1: direct regulation through membrane structure modification

Lipids acquired in diet, or by nutraceutic and pharmaceutic interventions can be incorporated into cell membranes, where they regulate the physico-chemical properties of membranes that, in turn, control the localization and activity of extrinsic membrane proteins (Fig. 2, panel 1). Thus, monomeric Gα proteins prefer lamellar membrane regions with high surface pressure, whereas dimeric or heterotrimeric G proteins prefer nonlamellar-prone microdomains with loose membrane surface packing [4,7]. This fact is due to the presence of a bulky isoprenyl moiety in the Gα subunit of G protein dimers and trimers that cannot penetrate well into bilayers with dense packing. By contrast, Gα proteins have fatty acyl moieties that prefer lamellar membrane structures. In this context, the presence of oleic acid but not its trans analogue (elaidic acid) in membranes causes changes in the lipid surface packing that alter G protein-mediated 2-adrenoceptor signaling with a greater potency than agonist ligands [8]. Moreover, anticancer drugs that regulate the membrane structure also regulate the interaction of G proteins with the membrane and downstream signaling [29,52].

Molecular chaperones [53] mediate the assembly of numerous proteins and degradation of misfolded proteins and are associated with membranes via specific lipid interactions [45,54]. The heat shock response (HSR) can be activated by diverse environmental and physiological stressors that result in the immediate induction of stress genes encoding heat shock proteins (Hsp), molecular chaperones, proteases and other proteins [55]. According to the denatured protein sensor hypothesis, misfolded or aggregated proteins disturbing cell homeostasis may represent a common sensory element [56]. However, membranes also sense environmental changes and, by altering their physical state and microdomain organization, they alter heat shock signals that activate Hsp transcription [42] (Fig. 3).

The formation of isofluid membrane states in response to the application of heat shock, the local anesthetic benzyl alcohol (BA), or other chemical agents results in almost identical increases in Hsp70 expression in B16F10 cells [57]. Importantly, BA-induced activation of Hsp expression is not triggered by a protein unfolding signal but rather by membrane hyperfluidization, which is followed by a rapid structural remodeling of the membrane lipids [58–63].

The raft components SM and Chol are also involved in the generation of second messengers in the HSR, and membrane stress caused by heat or chemical membrane fluidization augments the total Cer levels in Jurkat cells [64]. A direct link between heat-induced Cer production and the induction of specific stress proteins has been described in NIH WT-3T3 cells [65]. Application of the exogenous Cer analogue C2-Cer, or increasing
endogenous intracellular Cer induces the sHsp αβ-crystallin, but not the structurally related Hsp27. Cer has the unique property of fusing membranes and it appears to drive the coalescence of raft microdomains to form large, Cer-enriched membrane platforms that lack Chol [66,67]. Thus, elevated Cer levels rapidly displace Chol from the membrane/lipid-''Chol-raft'' to form a ''Cer-raft'' [68], which might be required for biochemical transfer of stress signals across the plasma membrane. Sphingosylphosphorylcholine (SPC), another sphingolipid metabolite activates Hsp27 via the p38 MAPK pathway in isolated rat cerebral arteries, unlike sphingosine-1-phosphate (S1P)[69]. By contrast, in osteoblast-like MC3T3-E1 cells and aortic smooth muscle A10 cells, S1P stimulates Hsp27 induction via the p38 MAPK and PI3K/Akt pathways [70–72]. In addition, during HSR, Chol can be rapidly converted to cholesteryl glucoside [73]. Indeed, exogenous cholesteryl glucoside rapidly activates the transcription factor HSF1 and induces the synthesis of Hsp70 in fibroblasts[74]. These findings suggest that lipids are important in fine tuning the expression of Hsp chaperones, which may prove beneficial in the treatment of several important diseases, such as cancer, diabetes and various neurodegenerative diseases [44].

A special case of Type 1 MLT is the so-called lipid replacement therapy. A well-known example of this approach is the substitution of membrane lipids in mitochondria. This organelle carries out oxidative phosphorylation to produce energy, so that it is more prone to produce reactive oxygen species that can damage mitochondrial lipids, especially in association with aging [75]. Some studies have demonstrated that therapeutic interventions with lipids and antioxidants can reduce mitochondrial lipid peroxidation and replace damaged lipids, which results in a reduction of fatigue in elderly subjects [76]. Altered mitochondrial membrane lipids affect the activity of important mitochondrial proteins, and treatments with cardiolipin, rich in the polyunsaturated fatty acid linoleic acid, restore the membrane lipid structure and activity of Ca2+ channels in mitochondria [77].

3.2. Type 2: regulation of enzymatic activity to alter membrane lipid levels

One example of Type 2 MLT is the effect of hydroxy-C18 unsaturated FAs (hydroxyoleic, hydroxylinoleic, hydroxy-α-linolenic and hydroxy-γ-linolenic acids) on SGMS [40]. The dramatic increases in SM levels following human cancer (lung, glioblastoma multiforme, astrocytoma, leukemia or in cell (A549, U118, SF767, Jurkat and others) treatment with these synthetic FAs (up to 500% following exposure for 72 h) produces significant alterations in the localization of pivotal proteins involved in cell proliferation, such as the translocation of Ras from the plasma membrane to the cytosol [40,41]. Alterations in the activity of enzymes that participate in the metabolism of sphingolipids (such as S1P or Cer) are implicated in many diseases, including cancer [78], suggesting that MLTs may be designed to regulate sphingolipid activity (Fig. 2 panel 2).

Changes in the composition of membranes are also observed in B16F10 cell cultures following thermal stress or benzyl alcohol treatment, which activates certain phospholipases (mainly PLA2 and PLC), and causes loss of polyenes (including the potent HSR modulator arachidonic acid, AA) and concomitant increases in

![Fig. 3. Overview of surface membrane-controlled signal transduction pathways that potentially control the expression of Hsps via HSF1. AA, arachidonic acid; Akt, protein kinase B; CaMKII, calcium/calmodulin-dependent protein kinase II; Cer, ceramide; Chol, cholesterol; DAG, diacylglycerol; DGL, diacylglycerol lipase; GFR, growth factor receptor; GSK3, glycogen synthase kinase-3; HSF1, heat shock factor 1; IP3, inositol triphosphate; MAPK, mitogen-activated protein kinase; MGL, monoacylglycerol lipase; PI3K, phosphoinositide 3-kinase; PI3P, phosphatidylinositol-3,4,5-trisphosphate; PKC, protein kinase C; PLA2, phospholipase A2; PLC, phospholipase C; PTEN, phosphatase and tensin homologue protein; Rac1, Ras-related C3 botulinum toxin substrate 1; S1P, sphingosine-1-phosphate; SM, sphingomyelin; Sfase, sphingomyelinasie; SPC, sphingosylphosphorylcholine. The figure is not intended to show the precise localization of all the components. For further details see text.](image-url)
saturated lipid species [58]. Moreover, in CHO cells at elevated, fever-type heat shock temperatures glycosyl-phosphatidylinositol labeled clusters (rafts) disappeared, which was accompanied by an increase in the expression of the small heat shock protein Hsp27 [60]. It is noted that in cell cultures, raft integrity spontaneously recovers at fever-like temperatures [79]. This effect causes redistribution of Chol-rich plasma membrane domains [61,80] and increased membrane lipid packing density in cell cultures [39], with a concomitant change in the localization of relevant signaling proteins. MLT drugs (Bimocolom, BGP-15) affecting the composition and dynamics of rafts can modulate the expression of certain hsp genes in different cell cultured cells [81–83].

3.3. Type 3: modulation of gene expression that results in changes in membrane lipid composition

Certain DNA-associated phospholipids are found in the nuclear matrix, where their regulatory roles are as yet unknown [84]. Many aspects of lipid metabolism and function in the cytoplasm are recapitulated in the nucleus, and thus, MLT can also target nuclear or other membranes [84]. The nuclear envelope contains the bulk of nuclear lipids, while the nuclear matrix contains enzymes and metabolites necessary for autonomous lipid metabolism in the nucleus [85]. The presence of nuclear lipids and their regulatory effects on numerous nuclear functions have been well documented (e.g., [85]). In this scenario, both the lipid-mediated regulation of nucleic acid function and the control of lipid composition in the nuclear membrane constitute potential activities with which MLT can interact.

Quiescent differentiated cells have high SM levels in the PM, whereas proliferating cells, including cancer cells, exhibit reduced PM SM content [40]. Direct addition of SM to the culture medium does not induce cell cycle arrest, whereas induction of SGMS and the subsequent increase in SM levels does inhibit cell growth and differentiation [40,41]. Interestingly, low nuclear SM has been associated with cell proliferation [86]. Because DNA synthesis is activated when sphingomyelinenase is active and SGMS activity is reversed, it could be speculated that part of the actions mediated by MLT could occur in the cell nucleus. In this scenario, MLT may be able to regulate gene expression, thereby modifying lipid composition (Fig. 1). Regulating the expression of genes that alter the lipid composition of the membrane can alter cell activity in various ways. The lipid-binding transcription factors PPARs, RXR, RAR and LXR, can be regulated by synthetic ligands, resulting in the modulation of membrane lipids and cell function [87]. Since lipids control the activity of PPARs and related transcription factors, the activity of these proteins could be regulated by hydrophobic MLT drugs, such as fatty acid analogues, whose partition coefficients are higher than those recommended by the Lipinski’s rule of 5 to design or discover drugs. This rule suggests (among other things) that the partition coefficient (log Poctanol/water) should be less than 5 and this may fail for certain MLT molecules, such as modified fatty acids [88].

3.4. Type 4: lipid alterations that affect protein–protein interactions in specific membrane microdomains

The modification of membrane lipids in this scenario affects the productive interaction of 2 signaling partners (Fig. 2 panel 4). Accordingly, the changes in membrane lipid composition and structure may alter a given microdomain or the affinity of one of the proteins involved in the transduction of a specific signal. For example, reductions in the PE:SM ratio diminish the RTK–Ras and Rac–Raf interactions at the membrane, provoking a concomitant reduction in MAPK-associated signaling and ultimately, in the proliferation of cancer cells [41].

In a similar fashion, membrane Chol profoundly affects the targeting of the small GTP-binding protein Rac1 to membranes and its interactions with other proteins [89]. The stress-stimulated PI3K-driven conversion of PI(2)P to PI(3)P has been proposed to activate Rac1 under mild, non-denaturing stress conditions [55], and Rac1 may be involved in mild HS-induced Hsp expression [90]. Accordingly, the redistribution of Chol-rich membrane domains may alter stress responses through Rac1-dependent mechanisms. Indeed, Rac1 inhibition by a specific inhibitor (NSC233766) halves HS-induced hsp25 expression at fever-like temperatures [79,91]. Clearly, there is a complex network of interconnected pathways that bridge the gap between the cell membrane and HSF-1 mediated modulation of the expression of Hsp chaperons (see Fig. 2).

Stress-induced inositol phosphate signals are generated within minutes and they turnover rapidly [92]. Rapid increases in cytosolic Ca++ levels [57,93] are a prerequisite for hsp transcription [94], although in human epidermoid A431 cells heat activates the Na+−Ca++ exchange system, thereby augmenting [Ca2+], while reducing [Na+], [95]. In addition, the HSR is triggered by calcium/calmodulin-dependent protein kinase II (CaMKII) which is activated by increases in [Ca2+], the binding of Ca++/calmodulin and by autophosphorylation [96]. The HSR can also be activated by both AA and PLA2 [97,98]. Exogenous PLA2 stimulates AA generation and release, while AA production can be driven by DAG lipase-MAG lipase metabolism of DAG. A positive correlation was recently demonstrated between HS response and cellular AA content [62]. Elevations in [Ca2+], PI3K phosphorylation and protein–protein interactions can regulate PLA2 activity [99]. Moreover, the generation of cis-un saturated FAs by PLA2 is crucial for the activation of PKC, and may stabilize PKC in an activated state [100,101]. AA may serve to direct Ca2+-sensitive and Ca2+-insensitive PKC isoforms to membrane targets, and mediate feedback modulation of Ca2+ signaling [102]. Furthermore, EGF signaling is transduced by two interconnected pathways, the PLC-PKC and MAPK pathways, which interact at two points. PKC activates MAPK, while MAPK can phosphorylate and activate cPLA2. The AA produced by cPLA2 can act synergistically with DAG to activate PKC [103], and AA can be further metabolized to eicosanoids that in turn mediate signaling via G protein-coupled receptors, and that may also induce HS response [104]. Moreover, AA can act within the cell, or it can cross cell membranes and act on neighboring cells [99]. PI(2)P is a substrate of PI3K in the production of PI(3)P, another lipid with key signaling functions and that plays a major role in the control of cell survival (e.g., stress response), growth and proliferation. The components of the PI3K pathway include upstream regulators of PI3K enzymes (such as EGFR and Ras), PTEN, various Ser/Thr kinases and transcription factors [105]. Several proteins propagate different cellular signals after binding to PI(3)P, including Akt and Rac1, both of which are important components of membrane-derived stress signal pathways. In addition, membrane depolarization increases Hsp70 expression in cultured skeletal muscle cells, and this effect is critically dependent on Ca2+ released from IP3-sensitive intracellular stores. Furthermore, depolarization-evoked slow Ca2+ signals induce PKC−α activation and its translocation to the nucleus, favoring HSF1 phosphorylation leading to increased Hsp70 expression [106].

Gangliosides, sialic acid-containing glycosphingolipids (GSLs), are expressed in a cell-type specific manner and they interact with a variety of molecules on plasma membranes through different non-covalent bonds, such as electrostatic and hydrophobic interactions. Through these interactions, ganglioside family members participate in diverse cell activities by forming dynamic functional complexes in living cell membranes (membrane microdomains or lipid raft) [107]. The expression of cellular gangliosides is influenced by various extracellular stimuli, including inflammatory
cytokines. Thus, the presence of gangliosides in membrane microdomains may reflect the characteristics of individual cells in a pathophysiological environment [108].

Insulin is critically dependent on caveolae/microdomains in adipocytes [109,110]. Due to their lower density, these microdomains can be isolated from cell membranes using sucrose gradient centrifugation (after cell disruption with non-ionic detergents at cold temperatures), and they are designated as “detergent-resistant membrane microdomains” (DRMs: [111,112]). Though DRMs are considered as experimental evidence of the existence of lipid rafts and related domains, including caveolae and glycolipid-enriched membrane microdomains (GEM: [111]), detergent-resistant membranes should not be assumed to resemble biological rafts in size, structure, or composition. Functional rafts may not be steady phenomena; they might form, grow, cluster or break up, shrink, and vanish according to functional requirements, regulated by rather subtle changes in the activity of membrane disordering or ordering compounds. However, these and other membrane domains have important functions in cells, such as attracting proteins with which they physically interact to propagate signals. Regulating these domains through interventions acting on GSLs may be of interest for the treatment of certain conditions, such as diabetes (see below).

G protein-coupled receptors (GPCRs) constitute the largest family of receptors in humans, and they mediate a large number of cell functions and currently constitute about 40% of all drug targets. Pepducins are lipidated peptides that target the GPCR-G protein interaction aided by a lipid tether, such as palmitic acid in specific membrane microdomains [113]. For example, AT-2341 targets the first intracellular loop of the chemokine receptor CXCR4 and pepducin-induced activation of this receptor results in blood cell mobilization, which is required prior to autologous bone marrow transplantation [114].

Finally, raft microdomain remodeling by monounsaturated (MUFA) MLT drugs regulates interactions with the Fas death ligand receptor, which clusters in defined membrane regions and oligomerizes in a ligand-free manner to activate the extrinsic caspase cascade, in this way selectively inducing leukemia cell death [115].

3.5. Type 5: direct MLT-drug binding to a protein that alters its membrane binding affinity or that of other signaling proteins

This mechanism of action (Fig. 2 panel 5) could be considered within the scope of conventional chemotherapy, as the drug binds to a protein rather than a lipid. However, the effect can be classed as MLT when the drug’s molecular mechanism of action is dependent on protein–lipid interactions (Fig. 2 panel 5). For example, farnesyl transferase and geranylgeranyl transferase inhibitors (e.g., Tipifarnib, which prevents Ras farnesylation) impair the binding of Ras and related proteins to membranes. This compound is currently used in various anti-cancer combination therapy protocols, and it prevents Ras from interacting with upstream (e.g., EGFR) and downstream (e.g., Raf) signaling proteins [116]. Thus, this type of drug indirectly inhibits the activity of the Ras-MAPK pathway by impairing Ras binding to the membrane and its subsequent interactions with other signaling partners [116]. Impairment of Ras binding to the plasma membrane has been associated with inhibition of cancer cell proliferation and subsequent induction of differentiation and death [41].

4. Therapeutic areas where MLT has been developed

In the following sections, therapies that modulate the lipid membrane that are currently under investigation are discussed.

4.1. Oncology

In the early 1980s, the anticancer drugs anthracyclines were shown to kill cancer cells by a direct interaction with the plasma membrane [117]. Agarose–doxorubicin complexes that cannot enter the cancer cells kill them [117] by modulating the membrane lipid structure, and subsequently altering the localization and activity of important signaling proteins [29]. Based on this pioneering study [29], several drugs were designed to regulate the membrane lipid structure with the aim of abolishing the off-target interactions of anthracyclines and improving their efficacy and toxicity profiles [8,52,101,115].

This research led to the rational design of 2-hydroxyoleic acid (Minerval) [101], which currently is in phase I/II clinical trials for glioma. Its presence in membranes causes order reduction in lamellar disordered regions (Ld, non-raft domains) [14,40,41]. In addition, it specifically activates SGMS, inducing a marked increase in SM levels in human cancer cells that enhances the order of the ordered lamellar domains [40] (Ld, lipid rafts). Minerval activates SGMS and induces dramatic increases in its product, SM, accompanied by massive reductions in the levels of its substrate PE. Treatment with Minerval causes normalization of membrane levels of PE and SM, and increases ca. 10-fold the SM:PE ratio [40].

Propofol-docosahexanoic acid (P-DHA) is another interesting molecule with an MLT-related mechanism of action. This molecule is a hybrid compound comprised of the anesthetic propofol covalently bound to DHA [118]. The therapeutic activity of this compound in vitro is unsurprising as both propofol and DHA alone exert anticancer effects. Potent anti-cancer effects have also been described recently for analogues of P-DHA, particularly for the treatment of breast cancer [119]. Another MLT-based anticancer drug is the alkyl lysophospholipid analogue edelfosine. This compound and its analogues alter the membrane lipid raft microdomain structure, initiating a series of molecular events that result in the induction of apoptosis in cancer cells [120]. However, due to its toxicity and modest efficacy, edelfosine could not complete all clinical phases and be authorized for marketing for the treatment of cancer.

Interestingly, the oncogenic antigen-519, a molecular marker found in breast cancer patients with poor prognosis, has been identified as FA Synthase (FAS) [121]. The potential use of FAS inhibitors is currently under investigation, and siRNA and chemical inhibitors of this target (e.g., C75, (−)-epigallocatechin-3-gallate) selectively induce cell growth inhibition and apoptosis of cancer but not normal cells in vitro [121,122]. Another chemical FAS inhibitor, orlistat (marketed under the trade name Xenical by Roche in most countries, and over-the-counter as Alli by GlaxoSmithKline in the UK and US), blocks growth and induces cell death in breast cancer cells when administered concurrently with the monoclonal antibody trastuzumab [123].

Alterations in lipid composition and lipid metabolism are beginning to be associated with tumorigenesis and cancer patient survival. For example, some lipid metabolism genes, such as, OLK1 and GLRX are upregulated in breast and prostate cancer tissues [124]. In this context, proteins related to fatty acid biosynthesis and lipid metabolism regulation, such as, ACC, FASN, INSIG1, and...
body weight decrease. Oleic and elaidic acid have the same chemical composition, but their different molecular structure causes divergent effects in the lipid bilayer structure [13], which has been shown to be associated with their opposite impact on protein–lipid interactions and human health [132]. In this context, the consumption of saturated (or trans–MUFA) fats has been linked with obesity and related health problems. Moreover, the saturated FA palmitic acid is a known inducer of endoplasmic reticulum (ER) stress and cell death [133]. Indeed, lipstatin, a potent natural inhibitor of pancreatic lipases and its derivative orlistat, a FAS (enzyme that mainly produces palmitate) inhibitor and lipid absorption blocker, are effective in the treatment of obesity [134].

4.2.2. Diabetes

Numerous studies demonstrate the association between the type of dietary fats consumed and the development of diabetes, which is placing a growing burden on medical care services for persons over 65 [135]. The ratio of saturated-to-unsaturated FAs in erythrocyte membranes of diabetic patients is greater than that observed in healthy controls (0.78 and 0.72, respectively) [136], which indicates the close relationship between lipids and diabetes. High oleic acid intake improves the glycemic status of these patients and it also reduces the levels of saturated FAs, while increasing those of unsaturated FAs, resulting in a reduction in the saturated-to-unsaturated FA ratio from 0.78 to 0.66. Moreover, it has been seen that concomitant with this effect, the levels of various G proteins in these elderly diabetics are significantly regulated in blood cells [136]. In this scenario, treatments with unsaturated FA derivatives have been shown to reduce glycemia in rats [137], while other molecules that regulate lipid turnover and metabolism (e.g., orlistat, see above) prevent type 2 diabetes. This control of the membrane lipid composition in animals and humans after treatment with natural oleic acid or synthetic analogues of this FA has been seen to be associated with changes in the membrane lipid surface packing (nonlamellar HII phase propensity), which regulates the interaction of some G proteins (relevant in metabolic signaling) with the membrane [8,13,136,137].

Membrane alterations affect signaling pathways from membrane lipids to hsp genes and Hsps themselves play fundamental roles in the etiology of several diseases, including type 2 diabetes [2]. Typically, the decreased expression of stress proteins in patients with type 2 diabetes correlates with reduced insulin sensitivity, while activation of Hsp70 by heat therapy improves clinical parameters [138,139]. The non-proteotoxic lipid-interacting hydroxicam acid (HA) and its derivatives physiologically restore the HS protein response, representing a new class of MLT pharmaceuticals [140]. At the molecular level HA derivatives are broad-spectrum, multi-target compounds that stabilize membranes and remodel their lipid rafts [79,81]. The HA derivative BGP-15, currently being tested in clinical trials for the treatment of diabetes (Table 1), remodels Chol-enriched lipid platforms in a similar manner to that observed following non-lethal heat priming or membrane stress [61,79]. BGP-15 also induces Hsp chaperone expression through the Rac1 signaling cascade, in accordance with the effects of Chol on the membrane-targeting of Rac1 [Fig. 3] [91].

Gangliosides (composed of a glycosphingolipid with one or more sialic acids linked on the sugar chain) modulate a variety of cellular processes (Fig. 4). TNFα produces a striking increase in cellular ganglioside GM3 levels in mouse 3T3-L1 adipocytes in a state of insulin resistance, and in the adipose tissues of obese/diabetic rodents, including Zucker fa/fa rats and ob/ob mice [141]. Treatment of adipocytes with TNFα revealed that the increased GM3 levels result in the elimination of insulin receptors (IRs) from DRM’s (while caveolin and flotillin are retained), effectively disrupting insulin metabolic signaling [142]. In agreement with these

### Table 1

<table>
<thead>
<tr>
<th>Gene</th>
<th>Down (n, %)</th>
<th>Intermediate (n, %)</th>
<th>Up (n, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2A9H</td>
<td>115 (33.5%)</td>
<td>224 (65.3%)</td>
<td>4 (1.2%)</td>
</tr>
<tr>
<td>FASN</td>
<td>101 (29.4%)</td>
<td>234 (68.2%)</td>
<td>8 (2.3%)</td>
</tr>
<tr>
<td>SMPD2</td>
<td>0 (0%)</td>
<td>288 (84.0%)</td>
<td>55 (16.0%)</td>
</tr>
<tr>
<td>SMPD3</td>
<td>74 (21.6%)</td>
<td>269 (78.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>PHH1</td>
<td>30 (8.7%)</td>
<td>311 (90.7%)</td>
<td>2 (0.6%)</td>
</tr>
<tr>
<td>SPTLC3</td>
<td>15 (4.4%)</td>
<td>197 (57.4%)</td>
<td>131 (38.2%)</td>
</tr>
<tr>
<td>SGMS1</td>
<td>84 (24.5%)</td>
<td>258 (75.2%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>SGMS2</td>
<td>16 (4.7%)</td>
<td>254 (74.1%)</td>
<td>73 (21.3%)</td>
</tr>
<tr>
<td>SPHK1</td>
<td>6 (1.7%)</td>
<td>283 (82.5%)</td>
<td>54 (15.7%)</td>
</tr>
<tr>
<td>SPHK2</td>
<td>20 (5.8%)</td>
<td>292 (85.1%)</td>
<td>31 (9.0%)</td>
</tr>
<tr>
<td>UGCG</td>
<td>21 (6.1%)</td>
<td>283 (82.5%)</td>
<td>39 (11.4%)</td>
</tr>
</tbody>
</table>

Analysis of the expression of 11 representative genes related to lipid metabolism and from the gene expression arrays from 343 patients with glioma taken from the REMBRANDT database (Glioma Molecular Diagnostic Initiative) [128]. Genes are listed with standard abbreviations. Down: Gene (mRNA) expression twofold below average. Intermediate: average expression. Up: twofold expression above average. The altered expression of these genes was found to be highly associated with changes in the median survival of the patient population and in ca. 90% of these glioma patients it was observed at least one alteration of the above genes. Adapted from [47].

SREBP1 are highly expressed in breast cancer tumors and associated with low patient survival [125] while colorectal carcinoma risk has been associated with hepatic lipase polymorphisms [126]. Analysis of the Cancer Genome Atlas (TCGA) database for 38 ovarian cancer samples demonstrated 39 differentially expressed lipid genes in ovarian cancer tissue compared to normal ovarian tissues [127].

Very recently the REMBRANDT database was analyzed to explore the potential role of lipid metabolism in the prognosis of individuals with brain cancer [128,129]. It was found that at least twofold down-regulated of SMG11 lowered very significantly the median of survival of patients with glialblastoma multiforme (a type of brain cancer): from approx 18 months in patients with intermediate expression to approx 10 months in patients with SMG1 downregulation [128]. Similar data were found in patients with glioma [47]. Moreover, the 10-year survival of glioblastoma multiforme patients with low SMG1 expression was approx 10-fold lower than that of patients with normal SMG1 expression. These data indicate the possible relevance of SM and other lipid metabolism genes in the malignant transformation in the various types of cancer studied so far [40,41]. Moreover, the highly frequent alterations in genes related to lipid metabolism induce a regulation in the median glioma patient survival from 22.6 months to 28 months [47,128].

Table 1

<table>
<thead>
<tr>
<th>Gene</th>
<th>Down (n, %)</th>
<th>Intermediate (n, %)</th>
<th>Up (n, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2A9H</td>
<td>115 (33.5%)</td>
<td>224 (65.3%)</td>
<td>4 (1.2%)</td>
</tr>
<tr>
<td>FASN</td>
<td>101 (29.4%)</td>
<td>234 (68.2%)</td>
<td>8 (2.3%)</td>
</tr>
<tr>
<td>SMPD2</td>
<td>0 (0%)</td>
<td>288 (84.0%)</td>
<td>55 (16.0%)</td>
</tr>
<tr>
<td>SMPD3</td>
<td>74 (21.6%)</td>
<td>269 (78.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>PHH1</td>
<td>30 (8.7%)</td>
<td>311 (90.7%)</td>
<td>2 (0.6%)</td>
</tr>
<tr>
<td>SPTLC3</td>
<td>15 (4.4%)</td>
<td>197 (57.4%)</td>
<td>131 (38.2%)</td>
</tr>
<tr>
<td>SGMS1</td>
<td>84 (24.5%)</td>
<td>258 (75.2%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>SGMS2</td>
<td>16 (4.7%)</td>
<td>254 (74.1%)</td>
<td>73 (21.3%)</td>
</tr>
<tr>
<td>SPHK1</td>
<td>6 (1.7%)</td>
<td>283 (82.5%)</td>
<td>54 (15.7%)</td>
</tr>
<tr>
<td>SPHK2</td>
<td>20 (5.8%)</td>
<td>292 (85.1%)</td>
<td>31 (9.0%)</td>
</tr>
<tr>
<td>UGCG</td>
<td>21 (6.1%)</td>
<td>283 (82.5%)</td>
<td>39 (11.4%)</td>
</tr>
</tbody>
</table>
bolic diseases, including type 2 diabetes. GM3 biosynthesis may prove beneficial for the treatment of metabolic syndrome (Fig. 4). Thus, novel therapeutic interventions aimed at inhibiting the localization of these receptors in caveolae is reportedly inter-acting with the development of Alzheimer’s disease (see Section 4.4.1).

Chol is one of the main constituents of cell membranes, where it plays structural and functional roles, contributing to the formation of membrane microdomains (e.g., lipid rafts), which act as signaling platforms. Nevertheless, high LDL/VLDL-associated Chol constitutes a major risk factor for the development of ather-oma plaques that decrease the size of the lumen of blood vessels thus increasing the likelihood of ischemic thrombi that cause atherosclerosis, stroke and myocardial infarction, etc. [147]. The impact of high Chol on health is underscored by widespread use of Lipitor (atorvastatin), which is the best-selling drug of all time [148]. In addition, high Chol levels and alterations in Chol metabolism have been consistently associated with the development of Alzheimer’s disease (see Section 4.4.1).

Metabolic syndrome is defined by the simultaneous occurrence of various risk factors that collectively increase the probability of developing type 2 diabetes mellitus and cardiovascular disease (Table 2) [151,152]. High intake of saturated and ω-6 FAs together with low intake of oleic acid and ω-3 FAs promotes the development of metabolic syndrome, while the inverse combination prevents its occurrence [153]. These data indicate that lipid derivatives, particularly FA-derived drugs, may play an important role in the treatment of metabolic syndrome. Because 2-hydroxyoleic acid efficaciously controls most symptoms associated with type 2 diabetes [108], a new pathological feature of insulin resistance in adipocytes has been proposed, whereby the dissociation of the IR-Cav1 complex occurs due to the downregulation of GM3S and the upregulation of GM2/GD2S expression. These observations suggest that each T cell subset contains unique rafts composed of different ganglioside species, and that these rafts serve distinct functions during different intracellular events following receptor-mediated stimulation. This ganglioside selection process may be crucial for the formation of distinct and functional lipid rafts in mature T cells.

findings, insulin signaling is enhanced in mice lacking GM3 synthase [143]. IRs form complexes with Cav1 and GM3 independently, and in GM3-enriched membranes IR mobility is increased by its dissociation from Cav1. As insulin metabolic signal transduction in adipocytes is critically dependent on caveolae, a new pathological feature of insulin resistance in adipocytes has been proposed, whereby the dissociation of the IR-Cav1 complex occurs due to IR-GM3 interactions in DRM microdomains [144] (Fig. 4). Thus, novel therapeutic interventions aimed at inhibiting GM3 biosynthesis may prove beneficial for the treatment of metabolic diseases, including type 2 diabetes [108].

Many receptor tyrosine kinases are localized in lipid rafts, including growth factors EGFRs, PDGFRs, and insulin receptor (IR), and all three of these receptor types carry a caveolin-binding motif in the cytoplasmic region [145]. Although the localization of these receptors in caveolae is reportedly interrupted by elevated levels of endogenous gangliosides, the precise mechanism underlying this phenomenon has not been determined yet [146]. Interestingly, like IRs, some of these growth factor receptors contain basic amino acids just above their transmembrane domains, driving spatial proximity to GEM [144].

4.2.4. Metabolic syndrome

Metabolic syndrome is defined by the simultaneous occurrence of various risk factors that collectively increase the probability of developing type 2 diabetes mellitus and cardiovascular disease (Table 2) [151,152]. High intake of saturated and ω-6 FAs together with low intake of oleic acid and ω-3 FAs promotes the development of metabolic syndrome, while the inverse combination prevents its occurrence [153]. These data indicate that lipid derivatives, particularly FA-derived drugs, may play an important role in the treatment of metabolic syndrome. Because 2-hydroxyoleic acid efficaciously controls most symptoms associated with this condition, it represents a serious candidate for monotherapy of metabolic syndrome [131,132,154,155].

4.3. Cardiovascular diseases: hypertension

Human erythrocyte cell membranes of hypertensive individuals contain more Chol, Chol esters and TAGs, and less phospholipids than normotensive subjects, in association with alterations in G protein activity [156]. In contrast, high oleic acid (MUFA) intake is associated with reduced blood pressure [157]. Moreover, the synthetic hydroxy fatty acid, 2-hydroxyoleic acid (MUFA), induces...
greater reductions in systolic blood pressure in hypertensive rats than oleic acid [132,154]. This dramatic reduction in blood pressure is mediated by the regulatory effects of membrane lipids, which increase adenylyl cyclase activity, activate PKA and reduce of Rho kinase expression [154].

Long chain ω-3 FA intake also provoke a reduction in blood pressure [158], while diets deficient in these FAs are associated with hypertension. Thus, dietary supplementation with ω-3 FAs, EPA and DHA, also induce blood pressure reductions and protection against myocardial infarction and ischemic stroke [160]. As described for MUFA, polyunsaturated FA (PUFA) intake influences the composition of the cell membrane, which in turn regulates its structural properties and controls the activity of membrane signaling proteins [161–163]. Finally, unsaturated FAs have been shown to have cardioprotective effects ([164] and references therein). Thus, 2-hydroxyoleic acid controls the transient outward K⁺ current (Ito) and the cytosolic Ca²⁺ transient levels in isolated cardiomyocytes, which has been associated with its normotensive effect [164]. By contrast, saturated FA and/or ω-6 FA intake have negative effects on blood pressure [153].

Inflammatory responses are inhibited by 2-hydroxyarachidonate [165], which may prevent neuronal death of brain penumbra area neurons after stroke, indicating its potential therapeutic use after post-ischemic events [137]. Various unsaturated FA analogues have also been shown to prevent atherosclerosis and improve cardiovascular health in general [137]. Similarly, HA derivatives may be useful for the treatment of atrial fibrillation [166] due to their heat-stress-like effect, which influences the abundance of Chol-microdomains.

4.4. Neurodegenerative disorders

After adipose tissue, the central nervous system (CNS) represents the largest location of lipids in the body. The myelin sheath of neuronal axons is formed by glial cells and consists of a succession of lipid bilayers. Certain neurodegenerative disorders are associated with demyelination or significant alterations in membrane lipids. These facts and the capacity of lipid drugs to interact with myelin and to cross the blood–brain-barrier (BBB) suggest that MLT may play a major role in the treatment of CNS disorders.

4.4.1. Alzheimer’s disease

Alzheimer’s disease is the most common neurodegenerative disease resulting in progressive dementia in the elderly (about 60–70% of all cases) [167]. The pathophysiology of Alzheimer’s disease is characterized by the loss of neurons and synapses, together with the accumulation of extracellular deposits of fibrillar β-amyloid (Aβ), known as senile plaques, and intraneuronal neurofibrillary tangles that are generated by the abnormal hyperphosphorylation of tau protein [168]. However, Bapineuzumab (Pfizer, ClinicalTrials.gov identifier NCT00663026), an antibody directed against Aβ plaques, failed to induce improvements in a phase III trial, which along with other findings suggests that these alterations may be downstream of more fundamental molecular/cellular events that perhaps involve membrane lipid alterations. In agreement with this suggestion, the efficacy of acetylcholinesterase inhibitors and NMDA blockers appears to be limited.

DHA is the most abundant FA in neuronal membranes in the cerebral cortex gray matter (about 40% of the polyunsaturated fatty acids esterified) and its decline is associated with age, and with the loss of memory and learning that accompanies Alzheimer’s disease [169,170]. Numerous epidemiological studies have demonstrated an inverse association between Alzheimer’s disease risk and ω-3 PUFA dietary intake [171]. The biophysical properties of DHA indicate that changes in its abundance may cause alterations in amyloid precursor protein (APP) proteolysis, receptor-mediated signaling and Tau protein phosphorylation. With the aim of reversing the structural and functional alterations induced by DHA loss, 2-hydroxy-DHA (LP226A1, Lipopharma) was designed, and tested in an animal model of severe Alzheimer’s disease (5xFAD mice). A 4-months treatment with this synthetic FA increased neurogenesis and restored cognitive scores in the radial maze test to control values [48,172]. In this context, γ-secretase cleavage occurs in an APP site located in the middle of the membrane, suggesting that the lipid environment may influence the production of amyloidogenic or non-amyloidogenic peptides, and that it may therefore be involved in Alzheimer’s disease pathogenesis [173]. In addition, there is mounting evidence implicating Chol in the pathogenesis of Alzheimer’s disease [174]. In fact, the regulation of Chol turnover by means of statins has been shown to reduce amyloid load [175,176]. Accordingly, biotech/pharma companies are currently developing statin derivatives to control Chol with a view to preventing or treating mild to moderate Alzheimer’s disease (e.g., ClinicalTrials.gov Identifier NCT00024531).

4.4.2. Spinal cord injury and other neurological conditions

A neurotrophic lipid factor formed by binding oleic acid to albumin in vitro induces significant motor recovery (~40%) in rats with spinal cord injury (SCI) [177] ameliorating both spasticity and pain. By contrast, elaidic acid, which is the trans isomer of oleic acid, causes no significant improvements in paralysis, spasticity or pain. Interestingly, oleic acid induces significant changes in the membrane structure, whereas elaidic acid has no such effect [13], indicating that the action of the former is mediated by structural effects. Similarly, LPA181, formed by the oleic acid analog, hydroxyoleic acid, and albumin, is more efficacious than the latter inducing motor recovery of ~80%, and ameliorating spasticity and pain [178].

HA and its derivatives may be useful for the treatment of broad range of neurological and neuromuscular diseases, including amyotrophic lateral sclerosis [179], Huntington’s disease [180] and muscular dystrophy [181].

Finally, ω-3 and ω-6 FA abnormalities have been implicated in the development of psychiatric diseases, such as schizophrenia and bipolar disorders [182,183], so that lipids may also be directly relevant to certain psychiatric disorders.

4.5. Other pathologies

HA derivatives have been shown to have the potential to ameliorate diverse acute and chronic conditions such as retinopathy [184], nephropathy [185], wound healing [186], acetaminophen liver toxicity [187], chemotherapeutic neuropathy [188], intracranial hemorrhage [189], atrial fibrillation [190], sunburn [191], ischemia reperfusion [192], vascular hypertension damage [193], myocardial infarction [194], mercuric nephropathy [195], brain hypoxia [196], pancreatitis [197], and ethanol intoxication [198].

Furthermore, MLT principles are being used to develop new therapeutic drugs to treat infectious diseases. As the lipid composition of bacterial lipid bilayers greatly differs from that of eukaryotic cells, it is possible to rationally design antimicrobial peptides that specifically form pores in the prokaryotic envelope without affecting the host, therefore overcoming resistance against other conventional antibiotics [199,200]. In addition to the treatment of bacterial infections, MLT approaches (i.e., edelfosine) have been designed to treat eukaryotic parasite infections, such as leishmaniasis [201]. Alkyl lysophospholipid derivatives (e.g., miltefosine) are also currently under development (phase II) for the treatment of antihistamine-resistant urticaria (ClinicalTrials.gov identifier
NCT01170949). Moreover, these molecules have proven efficacy for the treatment of rheumatoid arthritis, atopic dermatitis, cutaneous leishmaniasis, psoriasis and allergy [23,202].

AA is a relatively abundant FA in cells and it is a molecule that can act as a precursor of inflammatory mediators (e.g., prostaglandins, leukotrienes, thromboxanes). The COX/LOX inhibitor LP204A1 (AA analogue) readily crosses the BBB and prevents neuronal death in the penumbra area, in which inflammatory processes provoke the death of many neurons hours or days after a stroke [137,165,203].

5. Future directions and conclusions

In summary, MLT has emerged as a novel and innovative therapeutic concept that facilitates the design/discovery of new molecules. Molecules developed using this strategy target the membrane lipid boundary of cells and/or internal organelles, where many cellular functions occur. The development of such new drugs is aided by the identification of the factors regulating membrane lipid structures, and their roles in cell signaling and pathophysiological processes, and such information has allowed and will facilitate the design and discovery of novel molecules for the treatment of important diseases. This new knowledge may result in molecular modifications to improve the already demonstrated efficacy of MLT compounds or overcome certain limitations associated with their use.

The potential great of therapies that modulate the plasma membrane requires further contributions, such as new animal models of disease based on known lipid alterations, and the study of lipid alterations in existing animal models with the aim of evaluating MLT candidates. In addition, a deeper knowledge of membrane lipid structure and its effects on protein localization, protein–protein and –lipid interactions, cell signaling and physiopathology, would be necessary to discover or design new membrane-interacting drugs. Given the current state of the art of this field, oncology, neurodegenerative disorders and cardiovascular diseases appear to be areas where treatments with drugs targeted at the membrane could be highly efficacious.

Conflict of interest

The authors declare that there are no conflicts of interest.

Transparency Document

The Transparency document associated with this article can be found in the online version.

Acknowledgements

This work was supported in part by Grants BIO2013-49006 (Ministerio de Economía y Competitividad), Grups Competitius (Govern de les Illes Balears), the Marathon Foundation, by the Hungarian National Development Agency (TÁMOP-4.1.1.C-13/1/KONV-2014-0001) and the Hungarian Basic Research Fund (OTKA, NK100857, NN111006, NN112372). This work was also supported by research grants for a Grant-in-Aid for Scientific Research (B) and for Scientific Research on Innovative Areas (No. 23110002) from MEXT, Japan.

References


